I.A. DERMATOLOGY LIMITED

I.A. DERMATOLOGY LIMITED - Company Information

2022-04-012023-03-312023-03-31false08660823I.A. DERMATOLOGY LIMITED2023-12-3086900iso4217:GBPxbrli:pure086608232022-04-01086608232023-03-31086608232022-04-012023-03-31086608232021-04-01086608232022-03-31086608232021-04-012022-03-3108660823bus:SmallEntities2022-04-012023-03-3108660823bus:AuditExempt-NoAccountantsReport2022-04-012023-03-3108660823bus:FullAccounts2022-04-012023-03-3108660823bus:PrivateLimitedCompanyLtd2022-04-012023-03-3108660823core:WithinOneYear2023-03-3108660823core:AfterOneYear2023-03-3108660823core:WithinOneYear2022-03-3108660823core:AfterOneYear2022-03-3108660823core:ShareCapital2023-03-3108660823core:SharePremium2023-03-3108660823core:RevaluationReserve2023-03-3108660823core:OtherReservesSubtotal2023-03-3108660823core:RetainedEarningsAccumulatedLosses2023-03-3108660823core:ShareCapital2022-03-3108660823core:SharePremium2022-03-3108660823core:RevaluationReserve2022-03-3108660823core:OtherReservesSubtotal2022-03-3108660823core:RetainedEarningsAccumulatedLosses2022-03-3108660823core:LandBuildings2023-03-3108660823core:PlantMachinery2023-03-3108660823core:Vehicles2023-03-3108660823core:FurnitureFittings2023-03-3108660823core:OfficeEquipment2023-03-3108660823core:NetGoodwill2023-03-3108660823core:IntangibleAssetsOtherThanGoodwill2023-03-3108660823core:ListedExchangeTraded2023-03-3108660823core:UnlistedNon-exchangeTraded2023-03-3108660823core:LandBuildings2022-03-3108660823core:PlantMachinery2022-03-3108660823core:Vehicles2022-03-3108660823core:FurnitureFittings2022-03-3108660823core:OfficeEquipment2022-03-3108660823core:NetGoodwill2022-03-3108660823core:IntangibleAssetsOtherThanGoodwill2022-03-3108660823core:ListedExchangeTraded2022-03-3108660823core:UnlistedNon-exchangeTraded2022-03-3108660823core:LandBuildings2022-04-012023-03-3108660823core:PlantMachinery2022-04-012023-03-3108660823core:Vehicles2022-04-012023-03-3108660823core:FurnitureFittings2022-04-012023-03-3108660823core:OfficeEquipment2022-04-012023-03-3108660823core:NetGoodwill2022-04-012023-03-3108660823core:IntangibleAssetsOtherThanGoodwill2022-04-012023-03-3108660823core:ListedExchangeTraded2022-04-012023-03-3108660823core:UnlistedNon-exchangeTraded2022-04-012023-03-3108660823core:MoreThanFiveYears2022-04-012023-03-3108660823core:Non-currentFinancialInstruments2023-03-3108660823core:Non-currentFinancialInstruments2022-03-3108660823dpl:CostSales2022-04-012023-03-3108660823dpl:DistributionCosts2022-04-012023-03-3108660823core:LandBuildings2022-04-012023-03-3108660823core:PlantMachinery2022-04-012023-03-3108660823core:Vehicles2022-04-012023-03-3108660823core:FurnitureFittings2022-04-012023-03-3108660823core:OfficeEquipment2022-04-012023-03-3108660823dpl:AdministrativeExpenses2022-04-012023-03-3108660823core:NetGoodwill2022-04-012023-03-3108660823core:IntangibleAssetsOtherThanGoodwill2022-04-012023-03-3108660823dpl:GroupUndertakings2022-04-012023-03-3108660823dpl:ParticipatingInterests2022-04-012023-03-3108660823dpl:GroupUndertakingscore:ListedExchangeTraded2022-04-012023-03-3108660823core:ListedExchangeTraded2022-04-012023-03-3108660823dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-04-012023-03-3108660823core:UnlistedNon-exchangeTraded2022-04-012023-03-3108660823dpl:CostSales2021-04-012022-03-3108660823dpl:DistributionCosts2021-04-012022-03-3108660823core:LandBuildings2021-04-012022-03-3108660823core:PlantMachinery2021-04-012022-03-3108660823core:Vehicles2021-04-012022-03-3108660823core:FurnitureFittings2021-04-012022-03-3108660823core:OfficeEquipment2021-04-012022-03-3108660823dpl:AdministrativeExpenses2021-04-012022-03-3108660823core:NetGoodwill2021-04-012022-03-3108660823core:IntangibleAssetsOtherThanGoodwill2021-04-012022-03-3108660823dpl:GroupUndertakings2021-04-012022-03-3108660823dpl:ParticipatingInterests2021-04-012022-03-3108660823dpl:GroupUndertakingscore:ListedExchangeTraded2021-04-012022-03-3108660823core:ListedExchangeTraded2021-04-012022-03-3108660823dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2021-04-012022-03-3108660823core:UnlistedNon-exchangeTraded2021-04-012022-03-3108660823core:NetGoodwill2023-03-3108660823core:IntangibleAssetsOtherThanGoodwill2023-03-3108660823core:LandBuildings2023-03-3108660823core:PlantMachinery2023-03-3108660823core:Vehicles2023-03-3108660823core:FurnitureFittings2023-03-3108660823core:OfficeEquipment2023-03-3108660823core:AfterOneYear2023-03-3108660823core:WithinOneYear2023-03-3108660823core:ListedExchangeTraded2023-03-3108660823core:UnlistedNon-exchangeTraded2023-03-3108660823core:ShareCapital2023-03-3108660823core:SharePremium2023-03-3108660823core:RevaluationReserve2023-03-3108660823core:OtherReservesSubtotal2023-03-3108660823core:RetainedEarningsAccumulatedLosses2023-03-3108660823core:NetGoodwill2022-03-3108660823core:IntangibleAssetsOtherThanGoodwill2022-03-3108660823core:LandBuildings2022-03-3108660823core:PlantMachinery2022-03-3108660823core:Vehicles2022-03-3108660823core:FurnitureFittings2022-03-3108660823core:OfficeEquipment2022-03-3108660823core:AfterOneYear2022-03-3108660823core:WithinOneYear2022-03-3108660823core:ListedExchangeTraded2022-03-3108660823core:UnlistedNon-exchangeTraded2022-03-3108660823core:ShareCapital2022-03-3108660823core:SharePremium2022-03-3108660823core:RevaluationReserve2022-03-3108660823core:OtherReservesSubtotal2022-03-3108660823core:RetainedEarningsAccumulatedLosses2022-03-3108660823core:NetGoodwill2021-04-0108660823core:IntangibleAssetsOtherThanGoodwill2021-04-0108660823core:LandBuildings2021-04-0108660823core:PlantMachinery2021-04-0108660823core:Vehicles2021-04-0108660823core:FurnitureFittings2021-04-0108660823core:OfficeEquipment2021-04-0108660823core:AfterOneYear2021-04-0108660823core:WithinOneYear2021-04-0108660823core:ListedExchangeTraded2021-04-0108660823core:UnlistedNon-exchangeTraded2021-04-0108660823core:ShareCapital2021-04-0108660823core:SharePremium2021-04-0108660823core:RevaluationReserve2021-04-0108660823core:OtherReservesSubtotal2021-04-0108660823core:RetainedEarningsAccumulatedLosses2021-04-0108660823core:AfterOneYear2022-04-012023-03-3108660823core:WithinOneYear2022-04-012023-03-3108660823core:Non-currentFinancialInstrumentscore:CostValuation2022-04-012023-03-3108660823core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-04-012023-03-3108660823core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-04-012023-03-3108660823core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-04-012023-03-3108660823core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-04-012023-03-3108660823core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-04-012023-03-3108660823core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-04-012023-03-3108660823core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-04-012023-03-3108660823core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-04-012023-03-3108660823core:Non-currentFinancialInstrumentscore:CostValuation2023-03-3108660823core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-03-3108660823core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-03-3108660823core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-03-3108660823core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-03-3108660823core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-03-3108660823core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-03-3108660823core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-03-3108660823core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-03-3108660823core:Non-currentFinancialInstrumentscore:CostValuation2022-03-3108660823core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2022-03-3108660823core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2022-03-3108660823core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2022-03-3108660823core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2022-03-3108660823core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2022-03-3108660823core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2022-03-3108660823core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2022-03-3108660823core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2022-03-3108660823bus:Director12022-04-012023-03-31

Registered Number
08660823
(England and Wales)

Unaudited Financial Statements for the Year ended
31 March 2023

I.A. DERMATOLOGY LIMITED

Company Information
for the year from 1 April 2022 to 31 March 2023


Director	ALI, Iaisha, Dr


Registered Address	19 Sandy Lodge Road
	Rickmansworth
	WD3 1LP


Registered Number	08660823 (England and Wales)

I.A. DERMATOLOGY LIMITED

Balance Sheet as at
31 March 2023

	Notes	2023		2022
		£	£	£	£
Fixed assets
Tangible assets	5		49,264		24,428
Investments	6		312,240		223,200
			361,504		247,628
Current assets
Debtors	8	41,380		44,074
Cash at bank and on hand		1,355,846		1,062,417
		1,397,226		1,106,491
Creditors amounts falling due within one year	9	(238,306)		(204,891)
Net current assets (liabilities)			1,158,920		901,600
Total assets less current liabilities			1,520,424		1,149,228
Net assets			1,520,424		1,149,228
Capital and reserves
Called up share capital			100		100
Profit and loss account			1,520,324		1,149,128
Shareholders' funds			1,520,424		1,149,228

The company was entitled to exemption from audit for this reporting period under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The Director acknowledges their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime. The directors have chosen to not file a copy of the company’s profit and loss account.

The financial statements were approved and authorised for issue by the Director on 30 December 2023, and are signed on its behalf by:

ALI, Iaisha, Dr
Director
Registered Company No. 08660823

I.A. DERMATOLOGY LIMITED

Notes to the Financial Statements
for the year ended 31 March 2023

1.	Statutory information
	The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2.	Compliance with applicable reporting framework
	The financial statements have been prepared in compliance with FRS 102 Section 1A as it applies to the financial statements for the period and there were no material departures from the reporting standard.

3.	Accounting policies

	Turnover policy
	Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.

	Property, plant and equipment policy
	Tangible fixed assets are stated at cost or valuation less depreciation. Depreciation is provided on all tangible fixed assets as follows:


		Reducing balance (%)
	Plant and machinery	15

	Investment property policy
	Fixed assets investment relates to the company owning 40 shares in Devonshire Diagnostic Centre Limited.

	Revenue recognition policy
	Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.

Revenue recognition policy

Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.

	Taxation policy
	Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. Current or deferred taxation assets and liabilities are not discounted. Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Taxation policy

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or
substantively enacted by the balance sheet date.

	Foreign currency translation and operations policy
	Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.

Foreign currency translation and operations policy

Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.

	Leases policy
	Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

	Investments policy
	Investments in subsidiaries, associates and joint ventures are measured at cost less any accumulated impairment losses. Listed investments are measured at fair value where the difference between cost and fair value is material. Unlisted investments are measured at fair value unless the value cannot be measured reliably, in which case they are measured at cost less any accumulated impairment losses. Changes in fair value are included in the profit and loss account.

Investments policy

Investments in subsidiaries, associates and joint ventures are measured at cost less any accumulated impairment losses. Listed investments are measured at fair value where the difference between cost and fair value is material. Unlisted investments are measured at fair value unless the value cannot be measured reliably, in which case they are measured at cost less any accumulated impairment losses. Changes in fair value are included in the profit and loss account.

	Employee benefits policy
	The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

4.	Employee information


		2023		2022
	Average number of employees during the year	2		3

5.	Property, plant and equipment

	Plant & machinery	Total
	£	£
Cost or valuation
At 01 April 22	81,596	81,596
Additions	30,000	30,000
At 31 March 23	111,596	111,596
Depreciation and impairment
At 01 April 22	57,168	57,168
Charge for year	5,164	5,164
At 31 March 23	62,332	62,332
Net book value
At 31 March 23	49,264	49,264
At 31 March 22	24,428	24,428

6.	Fixed asset investments
	Fixed assets investment relate to the company owning 40 shares in Devonshire Diagnostic Centre Limited.

	Other investments¹	Total
	£	£
Cost or valuation
At 01 April 22	223,200	223,200
Revaluations	89,040	89,040
At 31 March 23	312,240	312,240
Net book value
At 31 March 23	312,240	312,240
At 31 March 22	223,200	223,200

	Notes
	¹Other investments other than loans

7.	Directors advances, credits and guarantees
	Director's current account credit balance of £129,207 (2022: £118,183) relates to to Dr Iaisha Ali

8.	Debtors

	2023	2022
	£	£
Other debtors	41,380	41,380
Prepayments and accrued income	-	2,694
Total	41,380	44,074


	Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.

Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.

9.	Creditors within one year

	2023	2022
	£	£
Taxation and social security	56,964	83,239
Other creditors	157,342	121,652
Accrued liabilities and deferred income	24,000	-
Total	238,306	204,891


	Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.